Lessee, Operating Lease, Liability, to be Paid, Year Three of CRISPR Therapeutics AG from 31 Mar 2019 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
CRISPR Therapeutics AG quarterly Lessee, Operating Lease, Liability, to be Paid, Year Three in USD history and change rate from 31 Mar 2019 to 31 Dec 2024.
  • CRISPR Therapeutics AG Lessee, Operating Lease, Liability, to be Paid, Year Three for the quarter ending 31 Dec 2024 was $28,704,000, a 2.4% decline year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year Three, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year Three, YoY Quarterly Change (%)

CRISPR Therapeutics AG Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Three (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $28,704,000 -$698,000 -2.4% 31 Dec 2024 10-K 11 Feb 2025 2024 FY
Q4 2023 $29,402,000 +$3,151,000 +12% 31 Dec 2023 10-K 21 Feb 2024 2023 FY
Q4 2022 $26,251,000 +$114,000 +0.44% 31 Dec 2022 10-K 21 Feb 2023 2022 FY
Q4 2021 $26,137,000 +$13,487,000 +107% 31 Dec 2021 10-K 15 Feb 2022 2021 FY
Q4 2020 $12,650,000 +$2,483,000 +24% 31 Dec 2020 10-K 16 Feb 2021 2020 FY
Q4 2019 $10,167,000 31 Dec 2019 10-K 12 Feb 2020 2019 FY
Q3 2019 $8,816,000 30 Sep 2019 10-Q 28 Oct 2019 2019 Q3
Q2 2019 $8,507,000 30 Jun 2019 10-Q 29 Jul 2019 2019 Q2
Q1 2019 $7,072,000 31 Mar 2019 10-Q 29 Apr 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.